Nucala Can Help Boost Remission Rates in EGPA Patients

Nucala Can Help Boost Remission Rates in EGPA Patients

293084

Nucala Can Help Boost Remission Rates in EGPA Patients

Nucala (mepolizumab) is effective and safe in combination with corticosteroids to treat eosinophilic granulomatosis with polyangiitis (EGPA), resulting in decreased disease activity and increased remission rates than standard treatment alone, a small study has found. Patients taking Nucala received significantly lower corticosteroid doses, suggesting that the treatment may allow for a reduction in total corticosteroid usage. The study, “Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis,” was…

You must be logged in to read/download the full post.